Advancing Digestive Health Through Science, Scale, and Sustainable Innovation:

At AMOLYT LIFESCIENCES, gastroenterology is a core growth and innovation pillar, reflecting our long-term commitment to improving digestive and liver health outcomes for India’s 1.4 billion people while contributing meaningfully to global disease management standards. As gastrointestinal disorders continue to rise in prevalence—driven by urbanization, metabolic risk factors, dietary transitions, and aging populations—we are focused on delivering clinically differentiated, affordable, and scalable medical solutions that address both national and international healthcare priorities.

India represents one of the world’s most complex and consequential gastroenterology landscapes. Our strategy is therefore designed to translate this complexity into leadership—leveraging India’s genetic diversity, evolving disease patterns, and healthcare scale to develop therapies that are locally relevant and globally benchmarked.

Our gastroenterology portfolio spans the full continuum of care, including acid-related disorders, inflammatory bowel disease (IBD), viral hepatitis, functional gastrointestinal disorders, metabolic liver disease, and advanced hepatology, ensuring continuity from early intervention to long-term disease control.

Our initiatives are closely aligned with national programs such as the National Programme for Prevention and Control of Non-Communicable Diseases and the Ayushman Bharat Digital Mission, while remaining harmonized with international clinical frameworks and guidance from the. Through this dual alignment, we are helping position India as a global hub for gastroenterology innovation and clinical excellence.

Corporate Vision and Strategic Direction

Our vision is clear and future-focused:

To significantly reduce the burden of digestive and liver diseases by enabling timely diagnosis, precision therapy, and sustained disease management—irrespective of geography or socio-economic status. To deliver on this vision, we are executing a set of disciplined and measurable strategic imperatives: Portfolio Strengthening and Therapeutic Leadership We continue to expand and optimize a differentiated gastroenterology portfolio that includes:

• Next-generation proton pump inhibitors (PPIs) with sustained-release and adherence-enhancing profiles
• Biologic therapies targeting TNF-α, integrin, and IL-23 pathways for moderate-to-severe IBD
• Direct-acting antivirals and nucleos(t)ide analogs for hepatitis B and C
• Neuromodulator-supported prokinetic therapies for IBS and gastroparesis
• Microbiome-based therapies, synbiotics, and FXR agonists addressing NASH and metabolic liver disease

Our development pipeline further incorporates novel small molecules, advanced diagnostics, and minimally invasive technologies aimed at improving outcomes while reducing long-term disease progression and healthcare costs.

India-Centric Innovation with Global Standards

We are investing significantly in India-anchored R&D and multi-omic clinical trials designed to meet USFDA, EMA, PMDA, and TGA regulatory expectations. This approach ensures faster access to innovation for Indian patients while maintaining global credibility and scalability.

Integrated Care Ecosystem

Through partnerships with 7,500+ hospitals, clinics, and diagnostic centers, we support an integrated care model capable of reaching over 30 million gastroenterology patients annually, strengthening specialist access across both metropolitan and non-metropolitan regions.

Digital Enablement and Data-Driven Outcomes

By embedding artificial intelligence, pharmacogenomics, and digital therapeutics into clinical pathways, we aim to meaningfully reduce diagnostic delays, hospitalization rates, and disease progression—particularly in NAFLD, IBD, and chronic liver disease.

Demonstrated Impact and Operational Excellence

Our gastroenterology strategy is underpinned by consistent execution and measurable results:

Expanded Access to Advanced Therapies: Deployment of biosimilar and innovative biologic therapies has enabled hundreds of thousands of patients with IBD to achieve improved disease control, reduced relapse rates, and fewer hospitalizations across India and select global markets.

Hepatitis and H. pylori Management Programs: Optimized antiviral and eradication regimens have significantly improved cure rates and reduced progression to advanced liver disease in high-burden regions.

Digital Transformation of Diagnostics: AI-assisted endoscopy, virtual gastroenterology consultations, and remote disease monitoring platforms have improved early detection, procedural accuracy, and continuity of care beyond urban centers.

These outcomes reflect our ability to combine clinical rigor, affordability, and scale within a sustainable healthcare framework.

Addressing an Evolving Disease Landscape

Digestive diseases are increasingly shaped by metabolic risk, environmental exposure, antimicrobial resistance, and lifestyle transitions. High out-of-pocket expenditure, delayed diagnosis, specialist shortages, and infrastructure gaps continue to challenge care delivery.

We address these realities through:

• Responsible antimicrobial stewardship
• Preventive screening and early intervention initiatives
• Technology-enabled supply chains and diagnostics
• Evidence-based engagement with policymakers and clinicians
• Each challenge reinforces our commitment to building resilient, future-ready gastroenterology solutions.
• Long-Term Commitment and Future Outlook

Guided by our core values of scientific excellence, ethical governance, patient-centricity, and collaborative innovation, we are making sustained long-term investments to strengthen gastroenterology research, manufacturing, and access.

Through strategic collaborations with the , the , global academic institutions, and leading medtech partners, we continue to enhance pharmacovigilance, accelerate translational research, and expand advanced care delivery.

Our ambition is clear: to improve digestive health outcomes for hundreds of millions of patients over the next decade, reduce disease-related disability, and establish India as a global reference point for gastroenterology innovation.

Because advancing digestive health is not only about treating disease—it is about restoring quality of life, productivity, and long-term well-being.